Thrombophilia and its impact on pregnancy

I. Pabinger

doi:10.1055/s-0037-1617170

Hämostaseologie, Table of Contents

Hamostaseologie 2008; 28(03): 130-134
DOI: 10.1055/s-0037-1617170

Original Article

Schattauer GmbH

Thrombophilia and its impact on pregnancy

Thrombophilie und Schwangerschaft

Authors

I. Pabinger

¹Clinical Division of Haematology and Haemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria

Abstract

Summary

In recent years thrombophilia has gained much attention as a risk factor for pregnancy complications. Whereas there is an established correlation between antiphospholipid-antibodies and pregnancy loss, data for other risk factors of thrombosis are less well established. Data suggest associations with antithrombin deficiency, hyperhomocysteinemia and also with factor V Leiden, prothrombin G20210A variation and protein S-deficiency. The association of thrombophilia with pre-eclampsia is still under discussion. A limited number of prospective studies did not reveal an increased risk for pregnancy complications in unselected women with thrombosis risk factors. In a single study low molecular weight heparin seemed to have a positive effect on pregnancy outcome after previous single or recurrent abortions. Experience in prevention of pre-eclampsia by administration of prophylactic heparin is very limited. Data on pregnancy complications in women with known heritable thrombophilia or a history of thrombosis are inconsistent as well. These women usually have a favourable pregnancy outcome. Conclusion: Thrombophilia screening might be justified in women with pregnancy loss. Treatment with low molecular weight heparin might be considered for those with pregnancy loss and thrombophilia. Further prospective studies and controlled interventional trials are urgently needed.

Zusammenfassung

In den vergangenen Jahren hat die Thrombophilie als Risikofaktor für Schwangerschaftskomplikationen große Beachtung gefunden. Während der Zusammenhang mit Antiphospholipid- Antikörpern und Aborten als gesichert gilt, ist dies für andere Thromboserisikofaktoren noch in Diskussion. Daten über Antithrombinmangel, Hyperhomocystein - ämie, Faktor-V-Leiden-Mutation und Prothrombin- G20210A. Variation sowie Protein-S-Mangel in Zusammenhang mit Aborten liegen vor, die Assoziation mit der Präeklampsie wird diskutiert. Eine limitierte Anzahl von prospektiven Studien konnte das erhöhte Risiko zwischen Thrombophilie und Schwangerschaftskomplikationen nicht schlüssig nachweisen. Eine einzige randomisierte Interventionsstudie mit niedermolekularem Heparin bei Spätaborten ergab ein sehr positives Ergebnis hinsichtlich der Verabreichung von Enoxaparin. Daten über Schwangerschaftskomplikationen bei Frauen mit bereits bekannter Thrombophilie oder einer Vorgeschichte von Thrombosen sind ebenfalls nicht übereinstimmend hinsichtlich des Risikos für Aborte und Präeklampsie. Bei diesen Frauen ist jedoch im Allgemeinen mit einem positiven Schwangerschaftsergebnis zu rechnen. Schlussfolgerung: Primäres Thrombophilie- Screening bei Schwangeren ist zurzeit nicht indiziert. Die Prophylaxe mit niedermolekularem Heparin bei rezidivierenden Spätaborten (nach der 10. Schwangerschaftswoche) und vorhandener Thrombophilie soll in Erwägung gezogen werden. Weitere prospektive oder Interventionsstudien sind dringend notwendig.

Keywords

Thrombophilia - pregnancy - fetal loss - abortion - pre-eclampsia - stillbirth

Schlüsselwörter

Thrombophilie - Schwangerschaft - Fehlgeburt - Präeklampsie - Totgeburt

Full Text

References

References
1 Bick RL. Recurrent miscarriage syndrome due to blood coagulation protein/platelet defects: prevalence, treatment and outcome results. DRW Metroplex Recurrent Miscarriage Syndrome Cooperative Group. Clin Appl Thromb Hemost 2000; 6: 115-125.
2 Clark P, Brennand J, Conkie JA. et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166-1170.
3 Stirling Y, Woolf L, North WR. et al. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176-182.
4 Comp PC, Thurnau GR, Welsh J. et al. Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986; 68: 881-885.
5 Bonnar J, McNicol GP, Douglas AS. Fibrinolytic enzyme system and pregnancy. Br Med J 1969; 3: 387-389.
6 Beller FK, Ebert C. The coagulation and fibrinolytic enzyme system in pregnancy and in the puerperium. Eur J Obstet Gynecol Reprod Biol 1982; 13: 177-197.
7 Sondheimer S. Abortion. Encyclopedia of Reproduction 1999; 1: 1-6.
8 Preston FE, Rosendaal FR, Walker ID. et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-916.
9 Rai R, Regan L, Hadley E. et al. Second-trimester pregnancy loss is associated with activated C resistance. Br J Haematol 1996; 92: 489-490.
10 Sanson BJ, Friederich PW, Simioni P. et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996; 75: 387-388.
11 Kupferminc MJ, Eldor A, Steinman N. et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9-13.
12 Gris JC, Ripart-Neveu S, Maugard C. et al. Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost 1997; 77: 1096-1103.
13 Grandone E, Margaglione M, Colaizzo D. et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997; 77: 822-824.
14 Martinelli I, Taioli E, Cetin I. et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000; 343: 1015-1018.
15 Younis JS, Brenner B, Ohel G. et al. Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss. Am J Reprod Immunol 2000; 43: 31-35.
16 Pihusch R, Buchholz T, Lohse P. et al. Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester. Am J Reprod Immunol 2001; 46: 124-131.
17 Alonso A, Soto I, Urgelles MF. et al. Acquired and inherited thrombophilia in women with unexplained fetal losses. Am J Obstet Gynecol 2002; 187: 1337-1342.
18 Rasmussen A, Ravn P. High frequency of congenital thrombophilia in women with pathological pregnancies?. Acta Obstet Gynecol Scand 2004; 83: 808-817.
19 Gris JC, Quere I, Sanmarco M. et al. Anti - phospholipid and antiprotein syndromes in nonthrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstetricians and Haematologists Study - NOHA. Thromb Haemost 2000; 84: 228-236.
20 Rai R, Shlebak A, Cohen H. et al. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod 2001; 16: 961-965.
21 Carp H, Salomon O, Seidman D. et al. Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. Hum Reprod 2002; 17: 1633-1637.
22 Dudding TE, Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb Haemost 2004; 91: 700-711.
23 Kovalevsky G, Gracia CR, Berlin JA. et al. Evaluation of the association between hereditary thrombo philias and recurrent pregnancy loss: a meta-analysis. Arch Intern Med 2004; 164: 558-563.
24 Rey E, Kahn SR, David M. et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901-908.
25 Hashimoto K, Shizusawa Y, Shimoya K. et al. The factor V Leiden mutation in Japanese couples with recurrent spontaneous abortion. Hum Reprod 1999; 14: 1872-1874.
26 Robertson L, Wu O, Langhorne P. et al. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132: 171-196.
27 Lindqvist PG, Svensson PJ, Marsaal K. et al. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 1999; 81: 532-537.
28 Murphy RP, Donoghue C, Nallen RJ. et al. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 2000; 20: 266-270.
29 Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003; 1: 433-438.
30 Kupferminc MJ, Fait G, Many A. et al. Low-molecular- weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy 2001; 20: 35-44.
31 Sanson BJ, Lensing AW, Prins MH. et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81: 668-672.
32 Tzafettas J, Mamopoulos A, Anapliotis A. et al. Thromboprophylaxis throughout pregnancy in women with previous history of recurrent miscarriages of unknown aetiology. Clin Exp Obstet Gynecol 2002; 29: 267-270.
33 Gris JC, Mercier E, Quere I. et al. Low-molecularweight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695-3699.
34 Saftlas AF, Olson DR, Franks AL. et al. Epidemiology of preeclampsia and eclampsia in the United States, 1979–1986. Am J Obstet Gynecol 1990; 163: 460-465.
35 Brenner B, Lanir N, Thaler I. HELLP syndrome associated with factor V R506Q mutation. Br J Haematol 1996; 92: 999-1001.
36 Dizon-Townson DS, Nelson LM, Easton K. et al. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996; 175: 902-905.
37 Van Pampus MG, Dekker GA, Wolf H. et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999; 180: 1146-1150.
38 Kosmas IP, Tatsioni A, Ioannidis JP. Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: a metaanalysis. J Hypertens 2003; 21: 1221-1228.
39 Kosmas IP, Tatsioni A, Ioannidis JP. Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 2004; 22: 1655-1662.
40 Morrison ER, Miedzybrodzka ZH, Campbell DM. et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002; 87: 779-785.
41 Caritis S, Sibai B, Hauth J. et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998; 338: 701-705.
42 Pabinger I, Grafenhofer H, Kyrle PA. et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 2002; 100: 1060-1062.
43 Conard J, Horellou MH, van Dreden P. et al. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63: 319-320.
44 Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 1996; 16: 742-748.
45 Tengborn L, Bergqvist D, Matzsch T. et al. Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis?. Am J Obstet Gynecol 1989; 160: 90-94.
46 Pabinger I, Nemes L, Rintelen C. et al. Pregnancyassociated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden. Hematol J 2000; 1: 37-41.
47 Brill-Edwards P, Ginsberg JS, Gent M. et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 2000; 343: 1439-1444.
48 Pabinger I, Grafenhofer H, Kaider A. et al. Risk of pregnancy-associated recurrent venous thrombo - embolism in women with a history of venous thrombosis. J Thromb Haemost 2005; 3: 949-954.
49 Triplett DA. Antiphospholipid antibodies and recurrent pregnancy loss. Am J Reprod Immunol 1989; 20: 52-67.
50 Meinardi JR, Middeldorp S, de Kam PJ. et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 1999; 130: 736-739.
51 Tormene D, Simioni P, Prandoni P. et al. The risk of fetal loss in family members of probands with factor V Leiden mutation. Thromb Haemost 1999; 82: 1237-1239.
52 Pabinger I, Grafenhofer H, Kaider A. et al. Preeclampsia and fetal loss in women with a history of venous thromboembolism. Arterioscler Thromb Vasc Biol 2001; 21: 874-879.
53 Vossen CY, Preston FE, Conard J. et al. Hereditary thrombophilia and fetal loss: a prospective followup study. J Thromb Haemost 2004; 2: 592-596.
54 Rai R, Cohen H, Dave M. et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314: 253-257.
55 Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-1589.
56 Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100: 408-413.
57 Bauersachs RM, Dudenhausen J, Faridi A. et al. EThIG Investigators. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 2007; 98: 1237-1245.
58 Greer IA, Nelson-Piercy C. Low-molecularweight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106: 401-407.